HLA-Cw*04 allele associated with nevirapine-induced rash in HIV-infected Thai patients

AIDS Research and Therapy

Volumn 6, Issue , 2009, Pages

  Likanonsakul, Sirirat ^a   Rattanatham, Tippawan ^a   Feangvad, Siriluk ^a   Uttayamakul, Sumonmal ^a   Prasithsirikul, Wisit ^a   Tunthanathip, Preecha ^a   Nakayama, Emi E ^b   Shioda, Tatsuo ^b  

^a MINISTRY OF PUBLIC HEALTH   (Thailand)

^b OSAKA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIGEN; NEVIRAPINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ALLELE; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE EXPRESSION; GENE FREQUENCY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RASH; THAILAND;

EID: 77954378516     PISSN: None     EISSN: 17426405     Source Type: Journal    
DOI: 10.1186/1742-6405-6-22     Document Type: Article

References (33)

1. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998, 338:853-860. 10.1056/NEJM199803263381301, 9516219.
2. Manosuthi W, Chottanapand S, Thongyen S, Chaovavanich A, Sungkanuparph S. Survival rate and risk factors of mortality among HIV/tuberculosis-coinfected patients with and without antiretroviral therapy. J Acquir Immune Defic Syndr 2006, 43:42-46. 10.1097/01.qai.0000230521.86964.86, 16885778.
3. Sabbatani S, Manfredi R, Biagetti C, Chiodo F. Antiretroviral Therapy in the Real World: Population-Based Pharmacoeconomic Analysis of Administration of Anti-HIV Regimens to 990 Patients. Clin Drug Investig 2005, 25:527-535. 10.2165/00044011-200525080-00005, 17532696.
4. Havlir D, Cheeseman SH, McLaughlin M, Murphy R, Erice A, Spector SA, Greenough TC, Sullivan JL, Hall D, Myers M, et al. High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection. J Infect Dis 1995, 171:537-545.
5. Anekthananon T, Ratanasuwan W, Techasathit W, Sonjai A, Suwanagool S. Safety and efficacy of a simplified fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) for the treatment of advanced HIV-infected patients: a 24-week study. J Med Assoc Thai 2004, 87:760-767.
6. Stern JO, Robinson PA, Love J, Lanes S, Imperiale MS, Mayers DL. A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients. J Acquir Immune Defic Syndr 2003, 34(Suppl 1):S21-33.
7. Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet 2000, 356:1423-1430. 10.1016/S0140-6736(00)02854-3, 11052597.
8. Kappelhoff BS, van Leth F, MacGregor TR, Lange J, Beijnen JH, Huitema AD. Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study. Antivir Ther 2005, 10:145-155.
9. Gangar M, Arias G, O'Brien JG, Kemper CA. Frequency of cutaneous reactions on rechallenge with nevirapine and delavirdine. Ann Pharmacother 2000, 34:839-842. 10.1345/aph.19258, 10928391.
10. Pollard RBRP, Dransfield K. Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection. Clin Ther 1998, 20:1071-1092. 10.1016/S0149-2918(98)80105-7, 9916603.
11. Ho TT, Wong KH, Chan KC, Lee SS. High incidence of nevirapine-associated rash in HIV-infected Chinese. Aids 1998, 12:2082-2083. 10.1097/00002030-199815000-00026, 9814883.
12. Pirmohamed M, Park BK. HIV and drug allergy. Curr Opin Allergy Clin Immunol 2001, 1:311-316.
13. Martin AM, Nolan D, James I, Cameron P, Keller J, Moore C, Phillips E, Christiansen FT, Mallal S. Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts. Aids 2005, 19:97-99. 10.1097/00002030-200501030-00014, 15627041.
14. Mallal S, Nolan D, Witt C, Masel G, Martin AM, Moore C, Sayer D, Castley A, Mamotte C, Maxwell D, James I, Christiansen FT. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 2002, 359:727-732. 10.1016/S0140-6736(02)07873-X, 11888582.
15. Gatanaga H, Yazaki H, Tanuma J, Honda M, Genka I, Teruya K, Tachikawa N, Kikuchi Y, Oka S. HLA-Cw8 primarily associated with hypersensitivity to nevirapine. Aids 2007, 21:264-265. 10.1097/QAD.0b013e32801199d9, 17197830.
16. Coopman SA, Johnson RA, Platt R, Stern RS. Cutaneous disease and drug reactions in HIV infection. N Engl J Med 1993, 328:1670-1674. 10.1056/NEJM199306103282304, 8487826.
17. Leetrakool N, Kunachiwa W, Dettrairat S, Kohreanudom S. Distribution of class I molecular HLA-A*, -B* and -Cw* in people living with HIV-1/AIDS in Chiang Mai province of Northern Thailand [Abstract]. Paper presented at: Int Conf AIDS, 11-16 July, 2004; Bangkok
18. Vitezica ZG, Milpied B, Lonjou C, Borot N, Ledger TN, Lefebvre A, Hovnanian A. HLA-DRB1*01 associated with cutaneous hypersensitivity induced by nevirapine and efavirenz. Aids 2008, 22:540-541. 10.1097/QAD.0b013e3282f37812, 18301070.
19. Fellay J, Shianna KV, Ge D, Colombo S, Ledergerber B, Weale M, Zhang K, Gumbs C, Castagna A, Cossarizza A, Cozzi-Lepri A, De Luca A, Easterbrook P, Francioli P, Mallal S, Martinez-Picado J, Miro JM, Obel N, Smith JP, Wyniger J, Descombes P, Antonarakis SE, Letvin NL, McMichael AJ, Haynes BF, Telenti A, Goldstein DB. A whole-genome association study of major determinants for host control of HIV-1. Science 2007, 317:944-947. 10.1126/science.1143767, 1991296, 17641165.
20. Carrington M, Nelson GW, Martin MP, Kissner T, Vlahov D, Goedert JJ, Kaslow R, Buchbinder S, Hoots K, O'Brien SJ. HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage. Science 1999, 283:1748-1752. 10.1126/science.283.5408.1748, 10073943.
21. Kaslow RA, Carrington M, Apple R, Park L, Munoz A, Saah AJ, Goedert JJ, Winkler C, O'Brien SJ, Rinaldo C, Detels R, Blattner W, Phair J, Erlich H, Mann DL. Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nat Med 1996, 2:405-411. 10.1038/nm0496-405, 8597949.
22. Cruse JM, Brackin MN, Lewis RE, Meeks W, Nolan R, Brackin B. HLA disease association and protection in HIV infection among African Americans and Caucasians. Pathobiology 1991, 59:324-328. 10.1159/000163671, 1910527.
23. Thio CL, Gao X, Goedert JJ, Vlahov D, Nelson KE, Hilgartner MW, O'Brien SJ, Karacki P, Astemborski J, Carrington M, Thomas DL. HLA-Cw*04 and hepatitis C virus persistence. J Virol 2002, 76:4792-4797. 10.1128/JVI.76.10.4792-4797.2002, 136132, 11967296.
24. Littera R, Carcassi C, Masala A, Piano P, Serra P, Ortu F, Corso N, Casula B, La Nasa G, Contu L, Manconi PE. HLA-dependent hypersensitivity to nevirapine in Sardinian HIV patients. Aids 2006, 20:1621-1626. 10.1097/01.aids.0000238408.82947.09, 16868443.
25. de Maat MM, ter Heine R, Mulder JW, Meenhorst PL, Mairuhu AT, van Gorp EC, Huitema AD, Beijnen JH. Incidence and risk factors for nevirapine-associated rash. Eur J Clin Pharmacol 2003, 59:457-462. 10.1007/s00228-003-0613-3, 12920493.
26. Ananworanich J, Moor Z, Siangphoe U, Chan J, Cardiello P, Duncombe C, Phanuphak P, Ruxrungtham K, Lange J, Cooper DA. Incidence and risk factors for rash in Thai patients randomized to regimens with nevirapine, efavirenz or both drugs. Aids 2005, 19:185-192. 10.1097/00002030-200501280-00011, 15668544.
27. Kiertiburanakul S, Sungkanuparph S, Charoenyingwattana A, Mahasirimongkol S, Sura T, Chantratita W. Risk factors for nevirapine-associated rash among HIV-infected patients with low CD4 cell counts in resource-limited settings. Curr HIV Res 2008, 6:65-69. 10.2174/157016208783571946, 18288977.
28. Antinori A, Baldini F, Girardi E, Cingolani A, Zaccarelli M, Di Giambenedetto S, Barracchini A, De Longis P, Murri R, Tozzi V, Ammassari A, Rizzo MG, Ippolito G, De Luca A. Female sex and the use of anti-allergic agents increase the risk of developing cutaneous rash associated with nevirapine therapy. Aids 2001, 15:1579-1581. 10.1097/00002030-200108170-00018, 11504993.
29. van Leth F, Andrews S, Grinsztejn B, Wilkins E, Lazanas MK, Lange JM, Montaner J. The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART. Aids 2005, 19:463-471. 10.1097/01.aids.0000162334.12815.5b, 15764851.
30. Manosuthi W, Sungkanuparph S, Tansuphaswadikul S, Inthong Y, Prasithsirikul W, Chottanapund S, Mankatitham W, Chimsuntorn S, Sittibusaya C, Moolasart V, Chumpathat N, Termvises P, Chaovavanich A. Incidence and risk factors of nevirapine-associated skin rashes among HIV-infected patients with CD4 cell counts <250 cells/microL. Int J STD AIDS 2007, 18:782-786. 10.1258/095646207782212289, 18005514.
31. Chantarangsu S, Mushiroda T, Mahasirimongkol S, Kiertiburanakul S, Sungkanuparph S, Manosuthi W, Tantisiriwat W, Charoenyingwattana A, Sura T, Chantratita W, Nakamura Y. HLA-B*3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in HIV-infected Thai patients. Pharmacogenet Genomics 2009, 19:139-146. 10.1097/FPC.0b013e32831d0faf, 19104471.
32. Imanishi T, Akaza T, Kimura A, Tokunaga K, Gojobori T. Allele and haplotype frequencies for HLA and complement loci in various ethnic groups. Paper presented at: Eleventh International Histocompatibility Workshop and Conference; 6-13 November, 1991, Yokohama, Japan 1991,
33. Delfino L, Morabito A, Longo A, Ferrara GB. HLA-C high resolution typing: analysis of exons 2 and 3 by sequence based typing and detection of polymorphisms in exons 1-5 by sequence specific primers. Tissue Antigens 1998, 52:251-259. 10.1111/j.1399-0039.1998.tb03040.x, 9802605.